Genmab: Janssen applies for approval for lung cancer drug in the US
Genmab's collaborative partner Janssen has submitted a Biologics License Application to the FDA for the lung cancer treatment amivantamab, which was developed from the basis on Genmab's Duobody technology.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
The license approval application to the US Food and Drug Administration concerns patients with metastatic non-small cell lung cancer (NSCLC) with a particular set of mutations. Furthermore, patients need to have had relapses after being treated with chemotherapy, according to an announcement from Genmab.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab ditches drug candidate
For subscribers
.jpg&w=384&q=75)
